



**The Oslo Medicines Initiative: Better access to effective, novel, high-priced medicines – a new vision for collaboration between the public and private sectors**

**Consultation with non-State actors: nongovernmental organizations and philanthropic organizations**

**Virtual meeting**  
**26 April 2021, 10:00–13:00 CET**

**31 March 2021**  
**Original: English**

## **Provisional agenda**

### **10:00–10:20 Opening**

- Welcome remarks
  - o Dr Hans Henri P. Kluge: WHO Regional Director for Europe
  - o Dr Bjørn-Inge Larsen: Secretary General, Ministry of Health and Care Services, Norway
  - o Dr Natasha Azzopardi Muscat: Director, Division of Country Health Policies and Systems, WHO/Europe

### **10:20–10:40 Overview of the Oslo Medicines Initiative**

- o Dr Audun Hågå: Director General, Norwegian Medicines Agency
- o Dr Sarah Garner: Acting Regional Adviser, Access to Medicine and Health Products, WHO/Europe

### **10:40–11:30 Exchange of views on the substantive themes within the mandate of the Oslo Medicines Initiative**

- o Chair: Dr Natasha Azzopardi Muscat

Statements and exchange of views by non-State actors, reflecting on the questions posed in the discussion document under the themes of the Oslo Medicines Initiative:

- o **SOLIDARITY** – achieving greater solidarity between stakeholders to meet the Sustainable Development Goals and improve access for patients in the WHO European region.
- o **TRANSPARENCY** – understanding how transparency can be used to build trust and support access.
- o **SUSTAINABILITY** – considering how to ensure a sustainable industry and health care systems.

**11:30–11:40 Break**

**11:40–12:40 Exchange of views on the substantive themes within the mandate of the Oslo Medicines Initiative (continued)**

- Chair: Dr Arne-Petter Sanne, Norwegian Directorate of Health

**12:40–13:00 Closing session**

- Summary of issues and next steps:
  - Dr Audun Hågå
  - Dr Sarah Garner
- Chair's closing remarks
  - Dr Natasha Azzopardi Muscat